Supervised exercise is as important as revascularization in aortoiliac peripheral artery disease

Original title: Supervised Exercise, Stent Revascularization, or Medical Therapy for Claudication Due to Aortoiliac Peripheral Artery DiseaseThe CLEVER Study. Reference: J Am Coll Cardiol. 2015;65(10):999-1009.

Percutaneous revascularization has been effective to treat claudication due to aortoiliac peripheral artery disease. However, supervised exercise can also offer benefits in terms of functional class and quality of life, at least in the short term. Long term benefits of supervised exercise in aortoiliac disease have not been studied yet.

The aim of this study was to report the efficacy at short term (18 months) of supervised exercise vs. optimal medical care (OMC). It included 111 patients, randomized to OMC alone, PCI and OMC, or supervised exercise and OMT. Primary end point included an objective treadmill walking performance test and subjective quality of life assessment. 

Peak walking time improved both for the supervised exercise group (5.0 ± 5.4 min) and the percutaneous revascularization group (3.2 ± 4.7 min) resulting both significantly superior to OMC alone (0.2 ± 2.1 min; p < 0.001 y p = 0.04, respectively). The difference between supervised exercise and percutaneous revascularization was not significant (p = 0.16).

Improvement in claudication onset time was, as expected, greater for supervised exercise. Several quality scales showed durable improvements, especially with revascularization, compared to supervised exercise and OMC. 

Conclusion

In patients with aortoiliac disease, supervised exercise and percutaneous revascularization showed comparable and durable benefits, both strategies being superior to OMC alone.

Editorial Comment

Percutaneous revascularization has an advantage, because patients improve immediately after procedure and do not need to make an effort to overcome symptoms to keep walking. This may seem unimportant, but it had great impact in all quality of life assessment questionnaires. 

SOLACI

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....